98%
921
2 minutes
20
Interleukin-6 (IL-6) is a potential therapeutic target for many diseases, and it is of great significance in accurately predicting IL-6-induced peptides for IL-6 research. However, the cost of traditional wet experiments to detect IL-6-induced peptides is huge, and the discovery and design of peptides by computer before the experimental stage have become a promising technology. In this study, we developed a deep learning model called MVIL6 for predicting IL-6-inducing peptides. Comparative results demonstrated the outstanding performance and robustness of MVIL6. Specifically, we employ a pre-trained protein language model MG-BERT and the Transformer model to process two different sequence-based descriptors and integrate them with a fusion module to improve the prediction performance. The ablation experiment demonstrated the effectiveness of our fusion strategy for the two models. In addition, to provide good interpretability of our model, we explored and visualized the amino acids considered important for IL-6-induced peptide prediction by our model. Finally, a case study presented using MVIL6 to predict IL-6-induced peptides in the SARS-CoV-2 spike protein shows that MVIL6 achieves higher performance than existing methods and can be useful for identifying potential IL-6-induced peptides in viral proteins.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijbiomac.2023.125412 | DOI Listing |
J Biochem Mol Toxicol
September 2025
Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA.
Microbiota, which plays a vital role in susceptibility to Clostridioides difficile infection (CDI), synthesizes butyrate. Enteric glia is a component of the enteric nervous system (ENS) and is affected by C. difficile toxins A (TcdA) and B (TcdB).
View Article and Find Full Text PDFCurr Med Sci
August 2025
Department of Urology, Wuxue First People's Hospital, Wuxue, 435400, China.
Objective: Overactive bladder, a storage syndrome characterized by urinary urgency, frequency, and nocturia with or without urgency urinary incontinence, severely affects the quality of life of patients. The aim of this study was to investigate the role and mechanism of the C/EBP homologous protein in the overactive bladder.
Methods: An overactive bladder mouse model was established via the intraperitoneal injection of cyclophosphamide in wild-type and Chop-deficient mice.
J Exp Med
September 2025
Department of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.
In the tumor microenvironment (TME), cancer-associated fibroblasts (CAFs) play a crucial role in promoting tumor progression by creating an immunosuppressive environment through cytokine secretion and antigen presentation. While previous studies have demonstrated that CAFs exhibit distinct metabolic profiles compared with normal fibroblasts, it remains unclear how these metabolic programs influence the immune landscape within tumors and which factors drive metabolic reprogramming in CAFs. Here, we found that glutamine synthesis by CAFs promotes the polarization of pro-tumorigenic tumor-associated macrophages (TAMs) and supports tumor growth by altering TAM composition, highlighting the pivotal role of CAFs in shaping the immunosuppressive TME.
View Article and Find Full Text PDFSci Rep
July 2025
Department of Genetics and Biochemistry, Center for Human Genetics, Clemson University, Clemson, USA.
Alternative polyadenylation results in different 3' isoforms of messenger RNA (mRNA) transcripts. Alternative polyadenylation in the 3' untranslated region (3'UTR) can alter RNA localization, stability and translational efficiency. The SERPINA1 mRNA has two distinct 3' UTR isoforms, both of which express the protease inhibitor α-1-antitrypsin (A1AT).
View Article and Find Full Text PDFBiotechnol J
June 2025
Immune Regulation Department, Immunology and Immunotherapy Direction, Center of Molecular Immunology, Havana, Cuba.
Tocilizumab is a monoclonal antibody (mAb) that recognizes human Interleukin 6 receptor alpha (IL-6Rα) and antagonizes IL-6 signaling. It is therefore used in the treatment of moderate to severe rheumatoid arthritis in patients with inadequate response to antirheumatic drugs, and in the treatment of systemic juvenile idiopathic arthritis. During the course of the Coronavirus Disease 2019 (COVID-19) pandemic, the potential application of Tocilizumab in severe inflammatory diseases was demonstrated.
View Article and Find Full Text PDF